We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Travel-associated acquisition of hepatitis C virus infection in patients receiving haemodialysis.
- Authors
Abdul Ghafur; Muhammad Raza; Wendy Labbett; Anuradha Chawla; Colette Smith; Siew Lin Ngui; Andrew Davenport; Anna Maria Geretti
- Abstract
Background. It has been proposed that hepatitis C virus (HCV)-infected patients with end-stage renal disease undergoing maintenance haemodialysis may lack HCV antibody (anti-HCV) despite chronic HCV viraemia. This carries important implications for the design of surveillance policies. Methods. To characterize the prevalence of antibody-negative/RNA-positive HCV infection, patients attending seven haemodialysis units underwent anti-HCV testing using a third-generation assay and HCV RNA testing using real-time PCR. Results. At screening, anti-HCV prevalence was 12/360 (3.3%; 95% CI 1.7–5.8%); 7/12 (58.3%) anti-HCV positive samples were HCV RNA positive. Among anti-HCV-negative samples, 2/348 (0.6%; 95% CI 0.2–2.1%) tested HCV RNA positive (genotype 1a). Retrospective testing of stored sera dated the infections to a period of holiday in the Indian subcontinent. The two infections were unrelated by HCV-NS5B sequencing. Only one of the two newly infected persons showed raised transaminases. Both developed anti-HCV within 8–13 weeks of follow-up. Prospective surveillance of travellers to resource-limited countries returning to the units showed a HCV incidence of 4/153 travel episodes (2.6%; 95% CI 0.7–6.6%) among 131 persons (3.1%; 95% CI 0.8–7.6%). Conclusions. Among haemodialysis patients in the United Kingdom, antibody-negative/RNA-positive HCV status is associated with newly acquired infection, rather than lack of antibody responses in chronic HCV infection. There is a significant risk of HCV infection associated with travel to resource-limited countries. Given that transaminase levels may be normal, HCV RNA testing is recommended in patients re-entering a dialysis unit following haemodialysis in settings where suboptimal infection control policies pose a risk of exposure to blood-borne viruses.
- Publication
Nephrology Dialysis Transplantation, 2007, Vol 22, Issue 9, p2640
- ISSN
0931-0509
- Publication type
Academic Journal
- DOI
10.1093/ndt/gfm202